嗜酸粒细胞性食管炎（eosinophilic oesophagitis, EoO）是一种慢性免疫介导/变应原介导的疾病，临床上以食管功能障碍的症状界定，病理表现为在没有局部或全身嗜酸粒细胞增多的继发性病因情况下，食管上皮出现嗜酸粒性细胞浸润。
必须存在食管活检显示食管上皮被嗜酸性粒细胞浸润，且每高倍视野下有≥15 个嗜酸性粒细胞 (eos/hpf)，才能考虑该诊断。
Consultant Paediatric Gastroenterologist
Chelsea and Westminster Hospital
JE is a member of the advisory board for Dr Falk Pharma, manufacturer of Jorveza, a new formulation of budesonide licensed for adults with eosinophilic oesophagitis (EoO), and Nurtricia for infant functional bowel disorders. She has received honoraria from Dr Falk Pharma to speak on EoO and has been sponsored by Dr Falk Pharma, Abbvie and Nutricia to attend national and international meetings. JE is a member of BSPGHAN IBD working group, medical advisor to CICRA and Coeliac UK, member of CCUK IBD working group, member of BSG EoE Guideline development group, member of NICE Guideline update committee for Crohn’s disease and ulcerative colitis, member of NICE Diagnostics, and sits on the NICE advisory committee for personalised treatment in Crohn's disease.
Dr Jenny Epstein wishes to gratefully acknowledge Dr Evan S. Dellon, the previous contributor to this topic.
ESD is an author of a number of references cited in this topic.
Professor of Medicine
DK has served on advisory boards (Adare, Receptos) and received research funding (Covidien).
Chief of the Division of Gastroenterology and Hepatology
First Department of Pediatrics
University of Athens
Agia Sofia Children’s Hospital
AP has received speaker’s honorariums from Nestle and Nutricia; research grants from Biogaia/Nutricia/Abbvie; consultant’s fee from Receptos.